Telmisartan and angiotensin-converting enzyme inhibitors (ACEIs) are both effective and widely used antihypertensive drugs targeting renin-angiotensinaldosterone system. The study aimed to estimate the efficacy and tolerability of telmisartan in comparison with different ACEIs as monotherapy in the treatment of hypertension. Cochrane Central Register of Controlled Trials, PubMed and Embase were searched for relevant studies. A meta-analysis of all randomized controlled trials fulfilling the predefined criteria was performed. A random-effect model was used to account for heterogeneity among trials. Twenty-eight randomized controlled trials involving 5157 patients were ultimately identified out of 721 studies. Telmisartan had a greater diastolic blood pressure (DBP) reduction than enalapril (weighted mean difference (WMD) 1.82, 95% confidence interval (CI) 0.66-2.99), ramipril (WMD 3.09, 95% CI 1.94-4.25) and perindopril (WMD 1.48, 95% CI 0.33-2.62). Telmisartan also showed a greater DBP response rate than enalapril (relative risk (RR) 1.15, 95% CI 1.05-1.26), ramipril (RR 1.34, 95% CI 1.11-1.61) and perindopril (RR 1.22, 95% CI 1.05-1.41). There was no statistical difference in DBP reduction or therapeutic response rate between telmisartan and lisinopril (WMD À0.30, 95% CI À0.65 to 0.05; RR 0.99, 95% CI 0.80-1.23, respectively). Telmisartan had fewer drug-related adverse events than enalapril (RR 0.57, 95% CI 0.44-0.74), ramipril (RR 0.44, 95% CI 0.26-0.75), lisinopril (RR 0.70, 95% CI 0.56-0.89) and perindopril (RR 0.52, 95% CI 0.28-0.98). The meta-analysis indicates that telmisartan provides a superior BP control to ACEIs (enalapril, ramipril and perindopril) and has fewer drug-related adverse events and better tolerability in hypertensive patients.
Introduction
Hypertension is a major risk factor for myocardial infarction, congestive heart failure, stroke, end-stage renal disease and even sudden death. 1 Benefits of consistent reduction of blood pressure (BP) to prevent end-organ damages are well established. 2 However, only 34% patients with hypertension are adequately controlled to a BP of p140/90 mm Hg, despite the fact that the importance of BP control has been recognized. 3 Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II type 1 receptor blockers (ARBs) are two kinds of effective and widely used antihypentisive drugs targeting renin-angiotensinaldosterone system. ACEIs prevent the generation of angiotensin II from angiotensin I, while ARBs exert their vasodilatation effect at the receptor level by inhibiting the binding of angiotensin II to the type 1 receptors, irrespective of whether angiotensin II is generated by renin-angiotensin cascade or in local tissues by other pathways. The direct blockade of angiotensin II to the type 1 receptors might be more effective than the indirect blockade of ACEIs. Unlike ACEIs, ARBs do not disrupt the degeneration of other peptides such as bradykinin, which may cause persistent dry cough and angioedema. The ARB telmisartan is an orally active and potent nonpeptide selective AT 1 antagonist with a long terminal elimination half-life of about 24 h in the patients with hypertension. 4 Telmisartan is an effective antihypertensive agent that provides smooth control of BP, with a low rate of adverse events profile compared with placebo, [4] [5] [6] and without cough that is frequently associated with ACEIs. 6 In addition, the lipophilic nature of its molecule should enhance its tissue penetration compared with other ARBs. 7 Telmisartan 80 mg given once daily provides a better BP control than losartan 50 mg or valsartan 80 mg. 8, 9 Telmisartan provides numerically greater weighted average reductions of diastolic BP (DBP) and systolic BP (SBP) than irbesartan and candesartan cilexetil. 10 The findings of the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) show that the combination of telmisartan with ramipril is associated with more adverse events without an increase in benefits in patients with vascular disease or high-risk diabetes. 11 Aiming to evaluate which drug was more eligible for patients with hypertension, we undertook a systematic review and meta-analysis to determine the clinical efficacy and tolerability of telmisartan in comparison with ACEIs as monotherapy in the treatment of hypertension.
Methods
We tried to identify and include all randomized controlled trials carried out to assess the efficacy and tolerability associated with the use of telmisartan compared with ACEIs in patients with hypertension.
Outcome measures
The primary efficacy variable was the reduction from the baseline to the end of treatment in clinical DBP and SBP. Second efficacy variables included the following: therapeutic response rates of DBP and SBP (DBP o90 mm Hg and/or a reduction of X10 mm Hg, 24-h mean ambulatory DBP o85 mm Hg and/or a reduction from baseline of X10 mm Hg; SBP o140 mm Hg and/or a reduction of X10 mm Hg, 24-h mean ambulatory SBP o130 mm Hg and/or a reduction from baseline of X10 mm Hg); reductions from baseline in ambulatory DBP and SBP in 24-h, the last 6-h, daytime and night time periods; and rate of cerebro-cardiovascular events. We also assessed the tolerability of the drugs by considering overall rates of withdrawal, withdrawal for adverse events, the number of patients experiencing adverse events, and the relationship between such events and the drugs administered to patients. . The search combined the terms related to 'telmisartan' ('Micardis', 'Pritor') with the terms related to ACEIs ('alacepril', 'benazepril', 'benazeprilat', 'captopril', 'ceranapril', 'cilazapril', 'cilazaprilat', 'delapril', 'enalapril', 'enalaprilat', 'fosinopril', 'fosinoprilic acid', 'imidapril', 'libenzapril', 'lisinopril', 'moexipril', 'moveltipril', 'altiopril', 'omapatrilat', 'perindopril', 'perindoprilat', 'quinapril', 'quinaprilat', 'ramipril', 'ramiprilat', 'rentiapril', 'saralasin', 'spirapril', 'temocapril hydrochloride', 'teprotide', 'trandolapril', 'zofenopril'), using Boolean operators and database-specific syntax. We also searched the reference lists of the original reports and meta-analyses of studies involving ARBs (retrieved through the electronic searches) to identify studies, which had not yet been included in the computerized databases.
Search strategy

Trials selection
Studies meeting the following selection criteria were included in this meta-analysis: (1) study design: prospective randomized controlled clinical trials; (2) population: patients with hypertension, with or without other diseases such as metabolic syndrome and chronic kidney diseases; (3) interventions: telmisartan versus ACEIs, used as monotherapy and (4) outcome variables: at least one of BP, therapeutic BP response rates, mortality, cerebrocardiovascular event rates, adverse events, withdrawal and cough was reported. Two reviewers (ZZ, GLX) independently assessed the eligibility of a trial to be included in our meta-analysis, and this was checked by another author (XYS). To avoid duplication, only the data from the latest series were included if the same group of patients were involved in different reports.
Data extraction
Data were independently abstracted for each identified trials by two researchers (ZZ, GLX), and any disagreement was resolved by discussion. Data were extracted from each study with a predesigned review form. The following data were included: the authors of each study, the year of publication, the design of the trial, the duration of the study, the number of the patients, the age of the patients, sex, baseline SBP/DBP values, end point SBP/DBP values, changes from baseline in SBP and DBP, the ambulatory SBP and DBP values and therapeutic response rates of SBP and DBP. In addition, we retrieved the number or proportion of adverse events, withdrawals, mortality and cerebro-cardiovascular events. Only the data associated with monotherapy were retrieved if the patients received monotherapy as well as a combination of other antihypertensive drugs once they were reported separately.
Qualitative assessment
The studies were appraised independently by two authors (ZZ, GLX) based on the standard criteria (generation of allocation concealment, intention-totreat analysis, blinding and loss to follow-up), and additional quantitative quality was assessed by using the scoring system developed by Jadad, 12 appropriately modified according to the treatments under study. The quality scoring system was as follows: (1) Was the study described as randomized (1 ¼ yes, 0 ¼ no)? (2) Was the study described as double-blind or prospective, randomized, openlabel, blinded-end point (PROBE) 13 (1 ¼ yes, 0 ¼ no)? (3) Was there a description of withdrawals and dropouts (1 ¼ yes, 0 ¼ no)? (4) Was the method of randomization well described and appropriate (1 ¼ yes, 0 ¼ no)? (5) Was the method of double-blind well described and appropriate (1 ¼ yes, 0 ¼ no)? (6) Deduct 1 point if methods for randomization or blinding were inappropriate.
Statistical analysis
Not all of the trials reported on all the outcomes of interest to our analysis. We undertook separate meta-analyses for each comparison and outcome. We combined the data by using a random-effect model on the assumption that variation in clinical characteristics and sample sizes in the study groups produced heterogeneity.
We summarized dichotomous data as relative risk (RR) and continuous data as weighted mean difference (WMD). When the authors reported mean BP reduction and standard deviation (s.d.) from the baseline to the end of treatment, we retrieved them directly. When the authors reported standard error (s.e.) instead of s.d., we calculated s.d. by using the formula: s.d. ¼ s.e. Â (N) 1/2 . When mean BP reduction and its s.d. were not available, we computed them by using the methods given by Cochrane handbook version 4.2.6.
14 The statistical analysis was carried out with RevMan version 4.2.
Sensitivity analysis
To evaluate the effect of methodological characteristics of studies on the results of this meta-analysis, the impact of the components of such characteristics on our meta-analysis was assessed by sensitivity analysis.
Results
The flow diagram ( Figure 1 ) showed the process of identifying studies eligible for inclusion in the metaanalysis. We obtained 169 full papers from 721 studies for detail evaluation. A total of 28 studies were included for final analysis, involving 5157 patients. Among the included studies, 21 were in English, 5 in Chinese, 1 in French and 1 in Russian. Fourteen trials were multi-center studies. Telmisartan was compared with enalapril in 13 trials, with ramipril in 6 trials, with lisinopril in 4 trials and with perindopril in 5 trials.
All included trials were prospective randomized controlled clinical trials. One trial had the maximum Jadad score of 5, 7 had a score of 4, 7 had a score of 3, 7 had a score of 2 and 6 had 1. Allocation concealment was adequate in 2 trials, inadequate in 7 trials (open label) and unclear in the remaining trials. Thirteen trials were double blind and six were single blind, with no report in the remaining trials. Finally, intention-to-treat principle was used to analyse the patients in 10 trials. Characteristics of the included trials were shown in Table 1 .
In one trial, 5 in which the patients were randomized to receive telmisartan 40, 80, 120 mg or enalapril 20 mg, we did not extract the data of telmisartan 40 and 120 mg to avoid potential duplication. So did in another trial. 15 Telmisartan versus enalapril Thirteen trials involving 1682 patients compared telmisartan with enalapril. 5, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] There was a greater reduction in both DBP and SBP with the use of telmisartan as compared with enalapril. Therapeutic response rates of DBP and SBP favored telmisartan (RR 1.15, 95% confidence interval (CI) 1.05-1.26; RR 1.18, 95% CI 1.02-1.38, respectively). There was significant difference that favored telmisartan in adverse events, drug-related adverse events and cough. Two patients suffered from angioedema in the enalapril group. 15, 22 There was no difference in severe adverse events (RR 0.57, 95% CI 0. Studies with no data on outcome variables (n=1) Figure 1 The diagram showing studies eligible for inclusion in the meta-analysis.
Meta-analysis comparing telmisartan with ACEIs Z Zou et al (Tables 2 and 3 , Figures  2 and 3 ).
Sensitivity analysis
There was no statistical difference in DBP reduction between the two groups on the analysis of studies only including fixed dosage in random-effect model (WMD 2.51, 95% CI À0.64 to 5.67). However, the difference was significant, which favored telmisartan in fixed-effect model (WMD 3.03, 95% CI 1.27-4.79, test for heterogeneity: Q ¼ 2.42, P ¼ 0.12, I 2 ¼ 59%). There was statistical difference that favored telmisartan in studies including only titration-to-response: DBP reduction (WMD 3.14, 95% CI 1.61-4.68) and therapeutic response rate of DBP (RR 1.38, 95% CI 1.08-1.75). The analysis including only high-quality trials also showed that a significant decrease of DBP that favored telmisartan (WMD 3.14, 95% CI 1.61, 4.68).
Telmisartan versus lisinopril
Four trials involving 886 patients compared telmisartan with lisinopril. 6, [33] [34] [35] There was no statistical difference in DBP reduction and therapeutic response rate of DBP between the two groups. There was a greater SBP reduction that favored lisinopril. There was no statistical difference between the two groups in both ambulatory DBP and SBP reduction, including 24-h, daytime and night-time periods. More drug-related adverse events and coughs occurred in the lisinopril group. Two patients suffered from angioedema 33 and no death or cardio-cerebrovascular event was reported in both groups (Tables 2  and 3 , Figures 2 and 3) .
Telmisartan versus perindopril
Five trials involving 708 patients compared telmisartan with perindopril. [36] [37] [38] [39] [40] There was a greater DBP reduction and therapeutic response rate of DBP in the telmisartan group. There was no statistical difference in SBP reduction and therapeutic response rate of SBP between the two groups (WMD 1.67, 95% CI À1.09 to 4.43; RR 1.24, 95% CI 0.90-1.72, respectively). More drug-related adverse Meta-analysis comparing telmisartan with ACEIs Z Zou et al events and coughs occurred in the perindopril group (Tables 2 and 3 , Figures 2 and 3 ).
Sensitivity analysis
There was no statistical difference on the analysis of studies by titration-to-response in DBP reduction in random-effect model (WMD 0.98, 95% CI À1.00 to 2.97). However, the difference was significant in fixed-effect model (WMD 1.25, 95% CI 0.01-2.50; test for heterogeneity: Q ¼ 1.37, P ¼ 0.24, I 2 ¼ 27%). Considering the overall tolerability, we found that telmisartan caused fewer adverse events, drugrelated adverse events, adverse events-related withdrawals and coughs than the four ACEIs. The overall possibility of drug-related adverse events was 10.4% in telmisartan group and 15.8% in ACEIs group, the overall adverse events-related withdrawal rate was 3.1% in the telmisartan group and 5.6% in the ACEIs group, and the overall possibility of cough was 1.7% in the telmisartan group and 8.8% in the ACEIs group. There were two patients in the lisinopril group and two in the enalapril group, respectively, who suffered from angioedema, while no patient in the telmisartan group suffered from it.
Discussion
Hypertension is currently one of the leading causes of morbidity and mortality in the world. 41 Despite the numerous drugs available for the treatment of hypertension, an adequate control of high BP has not yet been achieved in the vast majority of patients with hypertension.
This meta-analysis focused on the two kinds of widely used antihypertensive drugs. The results of this meta-analysis revealed that telmisartan provided a superior control of BP to enalapril, perindopril and ramipril, as evidenced by a greater DBP reduction and therapeutic DBP response rate than the three ACEIs. Earlier meta-analysis of 61 prospective observational studies involving one million patients with no earlier vascular diseases revealed that in each age group, the proportional difference in the risk of vascular death associated with a given absolute difference in BP was similarly down to at least 115/75 mm Hg, below which there was no obvious relationship. 42 A reduction in SBP of 2-3 mm Hg should have translated into a risk reduction of 4-5%. 11 The findings of ONTARGET showed that mean BP was slightly lower in the telmisartan group than in the ramipril group (0.9/0.6 mm Hg). However, concomitant antihypertensive drugs such as b-blockers and diuretics might influence the direct comparison of antihypertensive effect between the two drugs. 11 After excluding the interference of other antihypertensive drugs, a greater reduction of DBP 1.82, 3.09, 1.48 mm Hg and SBP 3.63, 2.95, 1.67 mm Hg compared with enalapril, ramipril and perindopril was found in the 
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Abbreviations: ACEIs, angiotensin-converting enzyme inhibitors; 95% CI, 95% confidence interval; NR, not reported; RR, relative risk.
A random-effect model was used to calculate RR and 95% CI.
a The difference was significant in fixed-effect model (RR 0.59, 95% CI 0.36, 0.99, P ¼ 0.04; test for heterogeneity:
Meta-analysis comparing telmisartan with ACEIs Z Zou et al present meta-analysis, which might have clinical benefits that favored telmisartan in the long run.
From the results of this meta-analysis, telmisartan was significantly more effective than ramipril in reducing BP throughout the 24-h dosing interval, daytime, night time and particularly during the last 6 h. The incidence of cerebro-cardiovascular events, such as myocardial infarction, stroke and myocardial ischaemia, peaks in the early morning hours, which coincides with the sharp rise of BP, occurring upon arising and awakening from overnight sleep and also with the waning pharmacodynamic effect of antihypertensive drugs taken once daily in the morning. 43, 44 In addition, the increased BP variability is independently associated with increased target-organ damage and cardiovascular events. 45, 46 The ARB telmisartan might be of benefit with smooth and sustained 24-h BP. On the contrary, ramipril produced a significant reduction that was restricted to the period corresponding to its peak effect. 28 Efficacy of antihypertensive drugs in reducing BP analysed by meta-analytical approach also revealed that telmisartan provided numerically greater weighted average reductions of DBP and SBP than enalapril and ramipril, which paralleled our findings. 10 The findings of ONTARGET showed that telmisartan was equivalent to ramipril in the patients with vascular diseases or high-risk diabetes. However, telmisartan monotherapy might show an increase in benefits to patients with hypertension in the long run with its better lowering BP effect, without the interference of so many other antihypertensive drugs in the ONTARTGET.
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This meta-analysis revealed that the incidence of drug-related adverse events, especially cough, was significantly lower in telmisartan compared with all the included four ACEIs. Although most adverse events were mild-to-moderate, telmisartan may result in better compliance as compared to the noncompliance or withdrawal of the treatment by ACEIs because of chronic, dry cough. 47 Thus, telmisartan might provide a better long-term BP Figure 2 Comparison of the effect of telmisartan and angiotensin-converting enzyme inhibitors (ACEIs) on therapeutic response of diastolic blood pressure (DBP). RR, relative risk; 95% CI, 95% confidence interval; N, number of patients.
control. The incidence of cough in ACEIs treatment was 8.8% in 2043 patients, parallel to the findings of the post-marketing surveillance of over 47 000 patients in France, which revealed that 11.3% in women and 7.8% in men treated with perindopril had a cough. 48 Strengths and limitations of the meta-analysis In contrast to an earlier review that identified three studies, 49 we examined 28 clinical trials, using a wider range of clinically relevant outcome variables, and focused on direct comparison of treatments with telmisartan and ACEIs as monotherapy, precluding the interference of other drugs. To avoid the potential influence of differences in administration procedures, we performed separate meta-analyses on fixed dose or titration-to-response. Other factors that could potentially influence the results of this meta-analysis, such as severity of hypertension and quality of trials were also evaluated.
One limitation of this meta-analysis was that our analysis of outcome variables was based on data pooled from studies of different durations. Some caution was therefore required in their interpretation. Another limitation of this meta-analysis is no report of cerebro-cardiovascular event in this metaanalysis because of comparatively short duration of the included studies. In addition, some of the included studies were poorly reported, with six trials scored 1 by Jadad score system.
Recommendations for future research to inform clinical practice Our meta-analysis shows that there is much evidence available to help deal with how telmisartan is compared in terms of efficacy and tolerability with Figure 3 Comparison of the drug-related adverse events of telmisartan and angiotensin-converting enzyme inhibitors (ACEIs). RR, relative risk; 95% CI, 95% confidence interval; N, number of patients.
ACEIs in the treatment of hypertension. Some comparative data are available for telmisartan to inform clinical practice. However, the lack of key comparative data such as the rate of cerebro-and cardiovascular events and mortality leaves doctors, commissioners and the public confused about how to use these drugs in relation to standard practice.
Pragmatic well-designed randomized controlled trials with long duration are needed to compare the effect of telmisartan with that of ACEIs in hypertensive patients. The outcome variables should include clinical and ambulatory BP reduction, BP control, BP response, cerebro-cardiovascular events, mortality and adverse events. In addition, it seems important to determine how well telmisartan works in those people who fail to respond adequately to ACEIs.
In conclusion, this meta-analysis showed that in hypertensive patients, telmisartan was more effective than ACEIs (enalapril, perindopril, ramipril) in BP control and had fewer adverse events than all the included four ACEIs. The ARB telmisartan is more recommendable than the analysed ACEIs as far as its lowering BP effect is concerned. However, The findings of TRANSCEND showed that telmisartan just modestly reduced the risk of the composite outcome of cardiovascular death, myocardial infarction and stroke in the patients intolerant for ACEIs. 50 In another randomized trial, Stergiou 51 showed that there were differences in the antihypertensive action of ACEIs and ARBs that might be clinically important. Thus, physicians should consider the individual patient's susceptibility to the drugs and the specific adverse events when prescribing the antihypertensive drugs.
